This article has been corrected to fix the following typos in the Study Identification and Selection paragraph: 29 articles (not 24) were shortlisted and put through quality assessment.
No competing interests declared.
. 2025 Sep 24;17(9):c318. doi: 10.7759/cureus.c318
Correction: Safety and Efficacy of Biologic Therapies (Ustekinumab and Vedolizumab) in the Treatment of Inflammatory Bowel Disease (IBD): A Systematic Review
Hafsa Ashraf
1,✉, Adiprasad Bodapati
2, Ayesha Hanif
1, Donatus K Okafor
3, Gitika Katyal
3, Gursharan Kaur
1, Safeera Khan
1
Hafsa Ashraf
1
Internal Medicine, California Institute of Behavioral Neurosciences & Psychology, Fairfield, USA
Find articles by Hafsa Ashraf
Adiprasad Bodapati
2
Medicne, California Institute of Behavioral Neurosciences & Psychology, Fairfield, USA
Find articles by Adiprasad Bodapati
Ayesha Hanif
1
Internal Medicine, California Institute of Behavioral Neurosciences & Psychology, Fairfield, USA
Find articles by Ayesha Hanif
Donatus K Okafor
3
Research, California Institute of Behavioral Neurosciences & Psychology, Fairfield, USA
Find articles by Donatus K Okafor
Gitika Katyal
3
Research, California Institute of Behavioral Neurosciences & Psychology, Fairfield, USA
Find articles by Gitika Katyal
Gursharan Kaur
1
Internal Medicine, California Institute of Behavioral Neurosciences & Psychology, Fairfield, USA
Find articles by Gursharan Kaur
Safeera Khan
1
Internal Medicine, California Institute of Behavioral Neurosciences & Psychology, Fairfield, USA
Find articles by Safeera Khan
Editors: Alexander Muacevic, John R Adler
1
Internal Medicine, California Institute of Behavioral Neurosciences & Psychology, Fairfield, USA
2
Medicne, California Institute of Behavioral Neurosciences & Psychology, Fairfield, USA
3
Research, California Institute of Behavioral Neurosciences & Psychology, Fairfield, USA
✉
Hafsa Ashraf ashrafhafsa@gmail.com
✉
Corresponding author.
Collection date 2025 Sep.
Copyright © 2025, Ashraf et al.
This is an open access article distributed under the terms of the Creative Commons Attribution License CC-BY 4.0., which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
PMCID: PMC12459745 PMID: 41000146
This corrects the article "Safety and Efficacy of Biologic Therapies (Ustekinumab and Vedolizumab) in the Treatment of Inflammatory Bowel Disease (IBD): A Systematic Review" in volume 15, e48338.